Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Lymphoma, T-Cell, Peripheral 1Esophageal Neoplasms 1Brain Neoplasms 1

Interventions

10-propargyl-10-deazaaminopterin 11Cyclophosphamide 8Prednisone 7Vincristine 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Doxorubicin 6belinostat 5Brentuximab Vedotin 5romidepsin 4mogamulizumab 4darinaparsin 4Vitamin B 12 4Gemcitabine 4Folic Acid 4selinexor 3denileukin diftitox 3Nivolumab 3Injections 3Bendamustine Hydrochloride 3tislelizumab 2tipifarnib 2tenalisib 2duvelisib 2Rituximab 2Lenalidomide 2HBI-8000 2Fenretinide 2E7777 fusion protein 2AFM13 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Peripheral × endostar protein × Clear all
NCT02520219 2015-08-11

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Nanjing NingQi Medicine Science and Technology Co., Ltd.

Phase 2 Unknown
60 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡